Nymox Announces New Appointment of Russell Thomson Ph.D. as Nymox Vice President of Quality and Regulatory Affairs

HASBROUCK HEIGHTS, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce the new appointment of Russell I. Thomson PhD, FRSC to the position of Nymox Vice President of Quality and Regulatory Affairs.  Dr Thomson is an authority in the field of Quality Assurance and Control in the chemical and pharmaceutical industries.

Dr. Thomson is a Fellow of the Royal Society of Chemistry (UK), a Chartered Chemist and Chairman of the Royal Society of Chemistry Qualified Persons Assessors Panel.  He has worked in the pharmaceutical industry in positions including Head of Quality and Director of QA and Regulatory Affairs, and as Consultant Qualified Person at numerous large and small drug manufacturing facilities in the EU and the US for over 20 years.  Dr. Thomson was a Chartered Scientist with The Science Council (UK) from 2004-2010 and Corporate Member of the South African Chemical Institute from 1980-1999. He received his PhD in Chemistry from the University of South Africa.

Dr. Paul Averback, CEO of Nymox said, "Management and the Board are extremely pleased to have Dr. Thomson take on the position of VP of Quality and Regulatory Affairs. This is a key management position at a crucial time in the Company’s history as we are soon to submit both an NDA in the U.S. and an MAA in Europe. Dr. Thomson will work closely with Dr. Mark Staples, Nymox VP for Chemistry Manufacturing and Controls, to jointly assure that Nymox's manufacturing standards are fully compliant with all US and international regulations. As VP of Quality and Regulatory Affairs, Dr. Thomson is responsible for all activities related to Quality Control and Quality Assurance of Nymox's manufacturing in the US and the EU. Russell is an authority on implementation of Quality Assurance for manufacturing in this sector and brings to Nymox his vast knowledge and practical experience. His appointment to VP of Quality and Regulatory affairs is great news for the Nymox team and our collaborators."



For more information please contact  or 800-936-9669.



Forward Looking Statements



To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2018, and its Quarterly Reports.

For Further Information Contact:

Erik Danielsen

Nymox Pharmaceutical Corporation

1-800-93NYMOX